Lipid metabolic signatures deviate in sepsis survivors compared to non-survivors

Waqas Khaliq a,1, Peter Großmann b,1, Sophie Neugebauer c,d, Anna Kleyman a, Roberta Domizi a, Sara Calcinaro a, David Brealey a, Markus Gräler c,e,f, Michael Kiehntopf d, Sascha Schäuble b, Mervyn Singer a,*

a Bloomsbury Institute of Intensive Care Medicine, Division of Medicine, University College London, Gower Street, London WC1E 6BT, UK
b Systems Biology and Bioinformatics, Leibniz Institute for Natural Product Research and Infection Biology, Hans Knöll Institute, Adolf-Reichwein-Straße 23, D-07745 Jena, Germany
c Center for Sepsis Control and Care (CSCC), Jena University Hospital, Am Klinikum 1, D-07747 Jena, Germany
d Center for Molecular Biomedicine (CMB), Jena University Hospital, Hans-Knöll-Str. 2, 07745 Jena, Germany
e Department of Anaesthesiology and Intensive Care Medicine, Jena University Hospital, Am Klinikum 1, D-07747 Jena, Germany

A R T I C L E   I N F O

Article history:
Received 7 July 2020
Received in revised form 3 November 2020
Accepted 4 November 2020
Available online 21 November 2020

Keywords:
Sepsis
Metabolomics
Safety corridor
Beta-oxidation
Fatty acid metabolism
Energy metabolism

A B S T R A C T

Sepsis remains a major cause of death despite advances in medical care. Metabolic deregulation is an important component of the survival process. Metabolomic analysis allows profiling of critical metabolic functions with the potential to classify patient outcome. Our prospective longitudinal characterization of 33 septic and non-septic critically ill patients showed that deviations, independent of direction, in plasma levels of lipid metabolites were associated with sepsis mortality. We identified a coupling of metabolic signatures between liver and plasma of a rat sepsis model that allowed us to apply a human kinetic model of mitochondrial beta-oxidation to reveal differing enzyme concentrations for medium/short-chain hydroxyacyl-CoA dehydrogenase (elevated in survivors) and crotonase (elevated in non-survivors). These data suggest a need to monitor cellular energy metabolism beyond the available biomarkers. A loss of metabolic adaptation appears to be reflected by an inability to maintain cellular (fatty acid) metabolism within a "corridor of safety".

© 2020 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Infection is a commonplace and usually self-limiting condition that improves either by natural host defense processes or with iatrogenic assistance with antibiotics and source control. For reasons still poorly understood, a proportion of infected patients develop sepsis, i.e. organ dysfunction through a dysregulated host response [1]. Such patients are at high risk of mortality, approximately a third in developed countries and likely higher in resource-poor countries [2]. Indeed, sepsis represents one of the major causes of death worldwide even in survivors, many develop long-term or even permanent physical and/or cognitive disability [3].

Sepsis can be interpreted as a pathogen-triggered imbalance of host damage and repair processes. It is a complex condition that can originate from a wide variety of pathogens and anatomical sites of infection. The molecular basis underlying both susceptibility and prognosis remain poorly understood with many fundamental questions still unanswered. Susceptibility and outcome are influenced by various factors including age [4], gender [5], comorbidity [6] and genetic predisposition [7–8]. The development of individualized intervention strategies (precision medicine) requires a thorough understanding of the molecular mechanisms underlying multiple organ failure. Metabolic dysregulation, leading to organ dysfunction and eventually to overt organ failure, is increasingly recognized as an important component of this process [9]. While mechanisms underlying the inflammatory response that initially drives the pathogenesis of sepsis are fairly well understood, downstream pathways including those driving metabolic deregulation remain elusive [1].

Even though metabolomics is a relatively new approach for studying infectious diseases, metabolite signals found in biological
samples can be used as infection biomarkers [10–14]. Metabolomics has also been successfully build classification models of response to therapy [15], to predict mortality [16–18] and to evaluate global differences between survivors and non-survivors after hospitalization for community-acquired pneumonia (CAP) and sepsis [19]. Metabolic, proteomic and clinical data have been combined to develop a multi-dimensional model that could predict survival in septic patients with high accuracy [20]. However, direct comparison of findings from different metabolomic studies is difficult due to biological (sample type used, e.g. plasma, urine) and technical variations, with the consequent risk of introducing bias [21,22].

In this study we performed a detailed metabolomic (188 metabolites) and biochemical (30 biochemical parameters) characterization in septic survivors and non-survivors commencing from their admission to intensive care. A critically ill control group consisted of non-septic survivors and non-survivors. Comparison was also made against plasma and tissue samples taken from an established rat fecal peritonitis model of sepsis [23–25] that allows early prognostication [24,25]. This enabled us to not only identify metabolic differences in septic patients related to survival, but to also reveal metabolic signatures and mechanisms specific to septic non-survivors compared to other causes of death, and to compare plasma and tissue metabolite levels.

2. Results

2.1. Patient characteristics of the study population

Thirty-three patients from the general intensive care unit (ICU) of University College London Hospitals NHS Foundation Trust were enrolled between January 2014 and April 2015. Cohort characteristics are shown in Table 1 with more detail on demographics provided in Supplementary Table S1. Twenty patients were diagnosed with sepsis whereas 13 patients had non-septic inflammatory or other non-infection related diagnoses causing organ dysfunction. Plasma samples were collected on day 0 (day of ICU admission) and on days 1, 2, 3, 5, 7, 14, 21 and 28 until death or discharge from the ICU. In total, 149 samples were collected, averaging 4–5 samples per patient and were subjected to metabolomic and biochemical analyses. 188 metabolites were identified from seven metabolite groups, including acylcarnitines, amino acids, biogenic amines, lysophosphatidylcholines (lysoPC), phosphatidylcholines (PC), sphingolipids (SM) and hexoses. Thirty biochemical parameters were quantified in addition in samples taken only from the septic patient group over days 0 to 3. An overview of the measured metabolites and biochemical parameters is shown in Supplementary Tables S2 and S3.

For subsequent analyses, patients were categorized into four groups: patients surviving diagnosed sepsis (Septic-S), patients not surviving diagnosed sepsis (Septic-NS), patients surviving any non-sepsis diagnosis (non-Septic-S) and patients not surviving any non-sepsis diagnosis in the ICU (non-Septic-NS). To determine whether metabolites can distinguish septic from non-septic causes of illness or can provide early evidences for patient survival fate, statistical, machine learning and an adaptation of a ‘survival corridor’ based on surviving patients analyses were carried out and are described next.

2.2. Higher variance in the metabolic profiles of septic non-survivors

Eight of the 20 septic patients died. A principal component analysis (PCA) biplot was performed to evaluate potential differences in biochemical characteristics between septic survivors (Septic-S) and non-survivors (Septic-NS). The first two principal components of the biochemical profile distances show a separation of Septic-S and -NS (PERMANOVA, q = 0.0015, Fig. 1A). Levels of low-density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and troponin T (TnT) had the largest influence on separation, with survivors having higher HDL and LDL cholesterol and lower AST, ALT and TnT values compared to Septic-NS.

When studying the metabolomic signatures of Septic-S and -NS patients, we also included data from the 13 patients who served in our study as non-septic (non-Septic-S and non-Septic-NS) controls. As shown in Fig. 1B, the metabolomic profiles form a ‘horseshoe shape’ where individual samples from each group are interspersed but the group centres are ordered such that Septic-S and Septic-NS patient samples tend to locate towards opposite tips. Levels of carnosine, aspartate, putrescine, C3-DC (C4-OH) and PC aa C36:0 were largely responsible for the opposite placing of Septic-S and Septic-NS patient samples within the PCA (Fig. 1B). The global metabolomic characteristics of Septic-NS patients differed significantly from Septic-S (PERMANOVA, q = 0.0011) and non-Septic patients (PERMANOVA, q = 0.015), revealing a unique signature of Septic-NS patients. The most pronounced differences between Septic-S and Septic-NS patient samples were observed in the sphingolipid, lysophosphatidylcholine and phosphatidylcholine metabolite groups (Supplementary Fig. S1A–F). There was significantly higher variance in the metabolomic profiles of Septic-NS compared to Septic-S patients (t-test, q = 5e−4, Fig. 1C) and also in non-Septic-S (t-test, q = 8e−5, Fig. 1C), non-Septic-NS (t-test, q = 0.033, Fig. 1C) and both non-Septic groups combined (t-test, q = 9e−5, Fig. 1C), suggesting a highly individualized metabolomic signature in non-survivor septic patients.

To further study how death from sepsis differs metabolically compared to non-septic causes, we examined differences between Septic-NS and non-Septic-NS. Distinct signatures were not found in global metabolomic characteristics of Septic-NS vs non-Septic-NS (PERMANOVA, q > 0.05, Fig. 1B). However, differences were observed in metabolic subgroups such as amino acids, phosphatidylcholines and sphingolipids (PERMANOVA, q = 0.041, q = 0.046 and q = 0.046, respectively, Supplementary Fig. S1), and in single metabolites (described below in detail). In contrast to septic patients, the metabolomic profile of non-Septic-NS patients varied similarly to that of non-Septic-S patients (t-test, q > 0.05, Fig. 1C). This also suggests that Septic-NS patients may constitute a rather unique group characterized by a highly variable response to infection.

2.3. Acylcarnitines and sphingolipid concentrations associate with sepsis survival

To further elucidate specific metabolic and biochemical processes linked to sepsis survival, we performed ANOVA comparing Septic-S vs -NS groups. In total, 59 metabolites and 11 biochemical variables differed statistically significant (q value < 0.05) at days 0–3 (Fig. 2A, Supplementary Table S4). The association of different metabolite groups with survival can be clearly visualized in the analysis. Among the significantly different metabolites, 11 of 15 assayed sphingolipids were higher in Septic-S, as were 4 of 11 lysylPCs and 28 of 76 phosphatidylcholines. However, of the 17 biogenic amines measured, only putrescine was significantly different (higher in Septic-NS). The differing acylcarnitines comprised mostly of short-chain acylcarnitines and were generally higher in Septic-NS patients. This trend was also observed for amino acids (higher in Septic-NS) but the converse was seen in lipids (lysoPC, PC and SM, higher in Septic-S).

Acylcarnitines are reversibly produced from their acyl-CoA counterpart by the enzymes carnitine palmitoyltransferase-1 and -2 (CPT1 and CPT2) for transport across the mitochondrial matrix.
Therefore, we mapped the acylcarnitines of Septic-NS patients (Supplementary Fig. S2, Fig. 2B). The Random Forest [27–28] and linear Support Vector Machine (SVM) [29–30] combined with leave pair out cross validation (cf. Material and Methods) on the two best features (validation AUC ≥ 0.977, respectively, Fig. 2B) achieved significant between Septic-NS and non-Septic-NS patients (lower in Septic-NS, log₂FC = −1.4, Supplementary Fig. S4, S5). This again suggests a unique metabolic process in Septic-NS patients compared to other causes of death. Similarly, lysoPC a C28:1, PC ae C32:2 and PC ae C42:1, and most of the short chain acylcarnitines also differed significantly between Septic-S and -NS patients (Fig. 2A, Supplementary Fig. S4) as well as between Septic-NS and non-Septic-NS patients (Supplementary Fig. S5). Both lysoPC a C28:1 (log₂FC = −0.42) and short chain acylcarnitines in Septic-NS patients were significantly lower compared to non-Septic-NS patients. From the biochemical parameters, albumin, LDL, HDL and total cholesterol were significantly lower in Septic-NS patients compared to non-Septic-NS, IHD = ischemic heart disease; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; TTP = thrombotic thrombo-cytopenic purpura; AKI = acute kidney injury; G-I = gastrointestinal.

Table 1
Patient cohort description.

|                      | Septic-S | Septic-NS | non-Septic-S | non-Septic-NS |
|----------------------|----------|-----------|--------------|---------------|
| n                    | 12       | 8         | 9            | 4             |
| Age – yr<sup>a</sup> | 68 ± 16  | 68 ± 13   | 53 ± 18      | 50 ± 19       |
| Weight – kg          | 72.3 ± 19| 78 ± 6    | 77 ± 8       | 79 ± 20       |
| SOFA score<sup>b</sup>| 6 ± 1    | 9 ± 3     | 7 ± 2        | 10 ± 1        |
| APACHE II score<sup>c</sup> | 14 ± 4 | 21 ± 5   | 16 ± 4       | 19 ± 3        |
| Length of ICU stay – d<sup>d</sup> | 7 ± 8 | 7 ± 30   | 17 ± 13      | 13 ± 11       |
| Max. Noradrenaline dose at Day 0 – μg/kg/min<sup>e</sup> | 0.40 ± 0.29 | 0.57 ± 0.29 | 0.06 ± 0.08 | 0.18 ± 0.13 |
| Male sex – n (%)     | 9 (75)   | 7 (88)    | 2 (22)       | 3 (75)        |
| Co-morbidities – n (%)|         |           |              |               |
| Diabetes<sup>d</sup> | 5 (42)   | 3 (38)    | 0 (0)        | 0 (0)         |
| Heart Failure        | 0 (0)    | 2 (25)    | 3 (33)       | 1 (25)        |
| Hypertension         | 7 (58)   | 3 (38)    | 2 (22)       | 1 (25)        |
| IHD                  | 0 (0)    | 1 (13)    | 3 (33)       | 1 (25)        |
| CKD                  | 2 (17)   | 1 (13)    | 0 (0)        | 0 (0)         |
| COPD<sup>d</sup>     | 4 (33)   | 3 (38)    | 0 (0)        | 0 (0)         |
| Active cancer        | 1 (8)    | 0 (0)     | 2 (22)       | 0 (0)         |
| β-blockers<sup>e</sup> | 7 (58) | 0 (0.0)  | 6 (67)       | 1 (25)        |
| Alcohol abuse        | 0 (0)    | 0 (0)     | 1 (11)       | 0 (0)         |
| Insulin              | 3 (25)   | 1 (13)    | 0 (0)        | 0 (0)         |
| Steroids             | 0 (0)    | 1 (13)    | 0 (0)        | 0 (0)         |
| Statin               | 2 (17)   | 3 (38)    | 4 (44)       | 1 (25)        |
| Social history – n (%)|         |           |              |               |
| Tobacco use          | 4 (33)   | 1 (13)    | 3 (33)       | 1 (25)        |
| Alcohol abuse        | 0 (0)    | 0 (0)     | 1 (11)       | 0 (0)         |
| Illicit drug use     | 0 (0)    | 0 (0)     | 1 (11)       | 1 (25)        |
| Type of admission – n (%)|    |           |              |               |
| Elective             | 0 (0.0)  | 0 (0.0)   | 3 (33)       | 1 (25)        |
| Emergency<sup>d</sup> | 12 (100)| 8 (100)  | 6 (67)       | 3 (75)        |
| Admission source – n (%)|     |           |              |               |
| Emergency department<sup>d</sup> | 5 (42) | 3 (38)  | 6 (67)       | 2 (50)        |
| Inpatient ward       | 3 (25)   | 2 (25)    | 3 (31)       | 1 (25)        |
| Theatres             | 4 (33)   | 1 (13)    | 0 (0)        | 1 (25)        |
| Other hospital       | 0 (0)    | 2 (25)    | 0 (0)        | 0 (0)         |
| Sepsis type – n (%)  |         |           |              |               |
| Intra-abdominal      | 5 (42)   | 3 (38)    | –            | –             |
| Community-acquired   | 7 (58)   | 5 (63)    | –            | –             |
| Other critical illness – n (%)|     |           |              |               |
| Femoral fracture     | –        | 2         | 0            |               |
| Cardiac arrest       | –        | 1         | 1            |               |
| Seizures             | –        | 2         | 0            |               |
| G-I bleed            | –        | 1         | 2            |               |
| TTP                  | –        | 0         | 1            |               |
| Pulmonary embolus    | –        | 2         | 0            |               |
| Myeloma-related AKI  | –        | 1         | 0            |               |

Superscript characters show significant differences between patient groups by Student’s t-test (continuous variables) or Fisher’s exact test (discrete variables) without multiple hypothesis correction:

a: Septic-S vs Septic-NS; b: non-Septic-S vs non-Septic-NS; c: Septic-NS vs non-Septic-NS; d: Septic-S (S + NS) vs non-Septic-(S + NS).

IHD = ischemic heart disease; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; TTP = thrombotic thrombo-cytopenic purpura; AKI = acute kidney injury; G-I = gastrointestinal.

2.4. Metabolomic signatures accurately predict sepsis survival

The observed differences in Septic-S and -NS patients led us to investigate whether metabolomic and biochemical profiling at day 0 could be used to accurately predict survival in septic patients. There was a perfect and near-perfect classification using Random Forest [27–28] and linear Support Vector Machine (SVM) [29–30] combined with leave pair out cross validation (cf. Material and Methods) on the two best features (validation AUC of 1.000 and 0.977, respectively, Fig. 2B). The Random
Forest-based classification identified C4-carnitine and lysoPC a C28:1 as the most important features, while the linear SVM-based classification identified lysoPC a C28:1 and C28:0. The performance of the model for classifying non-Septic-NS vs Septic patients was moderate to low with two features and even with up to six features did not exceed an AUC of 0.83 for Random Forest and 0.81 for SVM (Supplementary Table S5). This suggests that at least some of the features are not general markers for survival but specific for survival in septic patients. Although the cross-validation variant we used for validation is mathematically proven to approach the true AUC [31], the predictive power of our model remains to be confirmed in an external validation cohort to show its clinical relevance.

2.5. Deviations from a safety corridor defined by metabolomic profiles increase risk of mortality

Due to the large variability observed in Septic-NS patients we hypothesized that critical-for-survival metabolites could have been missed in the statistical comparison between Septic-NS vs -NS patients. Therefore we adopted the notion that, like glucose levels [32], an increased variability of metabolism could indicate an inappropriate host response in the critically ill. In other words, the concentration of a metabolite or a group of metabolites that deviate beyond a certain threshold from a survivor’s average range may signal metabolic dysregulation and hence an increased risk of adverse outcome.

To evaluate whether there is merit in this “safety corridor” concept, we defined the corridor as follows: for each metabolite measured in both Septic-NS and non-Septic-NS patients the minimum and maximum concentrations across all samples in these survival groups are determined and define the metabolite specific safety corridor. We restrict this analysis to the 125 metabolites with non-significant statistical differences between Septic-NS and -NS patients. Metabolite concentrations from compared cohorts (e.g. non-surviving patients) falling outside its respective corridor range are considered deviations and are considered harmful. In fact, the number of deviations in Septic-NS patients was substantial, suggesting that important metabolites were potentially missed in our initial statistical analysis. This also confirms our above findings for a highly dysregulated metabolism in Septic-NS patients.

The dysregulation was not limited to specific components of metabolism as deviations occurred in 110 of the 125 measured metabolites, and in all metabolite groups (Supplementary Table S4). Spurious deviations caused by the small sample size might have an impact however the “safety corridor” concept appears to work similarly well when examining metabolomic data collected on septic shock patients by Ferrario et al. [16]. In fact, 65 metabolites deviated among non-surviving septic patients in both our study and that of Ferrario et al., including 3 of 4 sphingolipids, 5 of 7 lysoPCs and 2 of 3 (acyl-)carnitines, while there was little overlap in significantly differing metabolites between the two studies (Supplementary Table S6).

Some of the deviations in our patients were more common than others. Of the 125 metabolites that did not differ significantly between Septic-NS and -NS patients (Supplementary Table S6) 41 deviated from the safety corridor in at least 4 of 12 NS (both septic and non-septic) patients (Fig. 3A). From these 41 metabolites, the acylcarnitine C18:1-OH and phosphatidylcholines PC ae C38:0, -C38:5, -C38:6 and -C42:0 were specific to Septic-NS and did not cross the safety corridor in any of the non-Septic-NS patients (simulation test, uncorrected p = 0.0039). There was only one metabolite group, the phosphatidylcholines, where all Septic-NS patients left the corridor. Looking at the individual metabolites 7 of 8 Septic-NS patients crossed the safety corridor for the phosphatidylcholine PC ae C42:3 (simulation test, q = 0.013) and 6 of 8 did so for PC ae C40:2 (simulation test, q = 0.013). Interestingly, there were two subsets of only two metabolites – PC ae C42:3 and C14, and PC ae C42:3 and C3:1 - where all eight Septic-NS patients crossed the safety corridor for at least one of the metabolites (simulation test, p < 0.001). For one metabolite, lysoPC a C24:0, there was a clear separation of three Septic-NS patient time courses from all...
Fig. 2. Statistical and machine learning analysis independently find C4 acylcarnitine and lysoPCs discriminative for survival from sepsis. (A) All metabolites and clinical parameters that differed significantly between Septic-S and Septic-NS, either overall on days 0–3 or at any specific day by ANOVA based on untransformed concentration values after FDR correction. The heatmap shows data between the 5th and 95th percentiles for each measurement. Grey spots mark unmeasured values. Metabolites in bold face differ also between Septic-NS and non-Septic-NS. (B/C) ROC curve and AUC values for test and validation sets after the two best features were selected by Tournament Leave Pair Out-Cross Validation-Recursive Feature Elimination (TLPPOCV-RFE) using Random Forests (B) or linear Support Vector Machines (C).
other patients where the concentrations were notably above rather than below that of the survivor patients; this suggests the existence of a high-risk Septic-NS subgroup (Fig. 3B).

2.6. Data-driven beta-oxidation kinetic modelling identifies differing enzyme concentrations for Septic-NS patients

We previously demonstrated that our long-term, fluid-resuscitated fecal peritonitis rat model of sepsis can be used to predict long-term survival with high accuracy as early as 3–6 h after administration of the infectious insult [24,25]. Surviving animals show clear signs of clinical improvement at the study endpoint. Since acquiring systematically human organ data is challenging, especially with respect to living patients, but to investigate potential contributions of different organ sites to differing metabolite concentrations across different sepsis cohorts, we repeated the analyses performed on patient blood samples using samples taken from rat heart, liver and plasma at 6 h (early phase of sepsis), 24 h (established phase) and 72 h (recovery phase) (Supplementary Table S7) instead. Although no rat that died of induced sepsis could be kept alive until 72 h, several short and medium chain acylcarnitine concentrations showed the same relative difference between Septic-S and Septic-NS rats in liver and plasma already until 24 h. This indicates that plasma metabolite levels resemble to some extent liver metabolite status. Metabolites that differ significantly between the septic groups were excluded.

Fig. 3. Deviations from a corridor of safety are abundant in lipid species even in the absence of statistical differences. Time courses of NS patients at days 0–3 where concentrations are outside the Septic- and non-S Septic-NS minimum to maximum range at any day (A) in at least 4 patients and (B) for lysoPC a C24:0. The scale in (A) is pseudo-logarithmic. Metabolites that differ significantly between the septic groups were excluded.
metabolites were more similar between liver and plasma than between heart and plasma at 24 h as shown by a respective lower p values derived from a r-test of ratio of means [33], Fig. 4A, Supplementary Table S8). Since rat plasma metabolite levels were indicative for liver metabolite status, and because the main (acyl-)carnitine transporter in human and rodent liver, organic cation transporter novel 2, favours acylcarnitine import from plasma [34], we parameterized a kinetic computational model of mitochondrial fatty-acid beta-oxidation with data from Septic- (NS, S) for days 0 to 3 to infer liver mitochondrial status from human plasma samples. We coupled the output of two separate versions (Septic-NS and Septic-S) of this model and fitted it to the ratio of metabolite levels for Septic-NS to the overall metabolite concentrations of Septic-NS and Septic-S (Septic-NS/Septic-NS + Septic-S). Computing a metabolite ratio yielded relative metabolite differences between Septic-NS and Septic-S which we assume to correlate between liver and plasma and allowed us to ignore absolute metabolite concentrations.

By investigating fitted parameters our model predicts increased enzyme concentrations for carnitine palmitoyltransferase 2 (CPT2) and medium–chain acyl-CoA dehydrogenase (MCAD) in Septic-S for days 0 to 3 (Fig. 4B). In line with these findings hepatic mRNA expression of these two enzymes was decreased in septic compared to non-septic mice [35–36]. In addition, we predicted substantially differing enzyme concentrations for medium/short-chain hydroxacyl-CoA dehydrogenase (MSCHAD), elevated in Septic-S and crotonase (CROT, elevated in Septic-NS), for which we could not find existing evidence within the literature. MSCHAD is responsible for NADH and ketaoyl-CoA production in the model, indicating reduced NADH availability in Septic-NS. The kinetic model CROT produces hydroxyacyl-CoA of different lengths, a prerequisite to deliver NADH or acetyl-CoA for further important metabolic functions. Of note, our model predicts elevated enzyme concentrations for CROT in Septic-NS, potentially counteracting NADH and downstream acetyl-CoA deficiency, or diverting enoyl-CoAs from the alternative degradation route via the mitochondrial trifunctional protein that does not utilize short chain acyl-CoAs. In line with our enzyme concentration predictions, steady state reaction fluxes (Fig. 4C) show higher fluxes through sink reactions for acetyl-CoA, NADH, and FADH₂ in Septic-S than in Septic-NS, 2, which potentially impacts further on metabolic energy functionality (Fig. 4D).

3. Discussion

In this study we characterized and integrated biochemical and metabolomic variables in septic and non-septic cohorts and delineated differences in septic non-survivors compared to other patient groups. Although our total cohort was relatively small, we confirmed that many of the previous findings comparing early host responses in sepsis survivors and non-survivors are relatively robust. There was greater variability in the metabolomic profile of sepsis non-survivors compared to survivors using all time points (up to 28 days) hinting that negative survival fate is accompanied by dysregulated multiple metabolite concentrations. Instead of individual metabolite perturbations, this rather points to substantially impeded cellular function. This is in line with the greater metabolomic variance in septic patients who died within the first 24 h of ICU admission [20]. Examining individual metabolites and metabolic groups, concentrations of putrescine, amino acids and acylcarnitines (specifically C4-carnitine) were higher in non-survivors while lysOCPs, PCs and SMs were lower, confirming previous studies [16,18,20]. In addition, Random Forest and Support Vector Machine analysis provided very good models with exceptionally high predictive accuracy to distinguish septic survivors from non-survivors using lysOCP a C28:1, C28:0 and C4-carnitine, which may be of particular importance for delineating survival risks. Of note, lysOCP a C28:1 and C28:0 have not been included as important features in previous predictive models [18,20]. Thus, metabolomics reflects a promising avenue for "prognostic enrichment" in personalized critical care and should be studied in more depth including e.g. larger scaled patient studies.

Our predictive models had lower discriminative power when classifying non-septic survivors and non-survivors, suggesting a specific signature of metabolic features unique to septic non-survivors. While the levels of several lysOCPs and sphingolipids differed significantly between sepsis survivors and non-survivors, this was not seen in the respective non-septic groups. Sphingolipid SM C22:3 shows an exceptionally large concentration difference between sepsis survivors and non-survivors. LysOCP a C28:1, a high-ranked featured metabolite in our predictive models across different machine learning algorithms, also differed significantly in abundance between septic and non-septic non-survivors, suggesting possible unique metabolic processes in those dying from sepsis.

Furthermore, due to the large variability in metabolomic profiling of sepsis non-survivors, we hypothesized that we may have overlooked critical-for-survival biological processes within our initial statistical analyses. Therefore, we adopted the notion of a "safety corridor" where deviations from a range of concentration values for specific metabolites could have an important impact on patient outcome. Our data, as well as an analysis of a dataset in similar patients [16], suggest that septic non-survivors are outside the safety corridor for three sphingolipids (SM C16:1, SM C24:1, SM (OH) C22:1) and five lysOCPs (a C16:1, C18:0, C18:2, C20:3 and C20:4). Septic non-survivors, but none of the non-septic non-survivors, also crossed the safety corridor for seven phosphatidylcholines. To the best of our knowledge, none of these phosphatidylcholines have been previously reported to be associated with clinical outcomes in sepsis. We postulate that deviations of these phosphatidylcholines from normal levels could lead to a metabolic dysregulation in their highly-interconnected lysOCPs and sphingolipids, ultimately contributing towards outcome. Of note, for the safety corridor analysis we included only metabolites for which statistical significant differences between survivors and non-survivors could not be determined given the relatively small sample count in our study. Though this approach allowed us to investigate our data from a different angle and revealed additional more subtle signals, it also asks for further confirmation in additional, ideally larger scaled patient cohorts including also surviving and non-surviving patients with sepsis as defined in our study.

Since a primary function of the liver is enhancing energy substrate availability through oxidation of fatty acids, the idea to test lipid metabolism in patients at risk using our identified deviating lipid metabolite concentrations is appealing. Accessing the liver directly is however challenging in humans whereas metabolite levels in plasma, a much more accessible media, could serve as a proxy for liver metabolism. Using a long-term rodent model of sepsis we indeed found that plasma metabolites resemble liver metabolites substantially better than heart-associated metabolites (Fig. 4A). This led us to the idea to parameterize a kinetic model of beta-oxidation with patient data where we predicted substantially deviating concentrations for enzymes involved in producing energy relevant metabolites, such as acetyl-CoA, NADH, and FADH₂. These metabolites serve as important energy donors; we previously reported that mitochondrial respiratory enzymes utilizing these substrates were significantly reduced in skeletal muscle sampled from eventual non-survivor septic patients [37]. The decreased metabolite levels suggest perturbed Krebs’ cycle activity in bioenergetically-active tissues such as liver and muscle and reflect down-regulation of key enzymes such as carnitine
palmitoyltransferase or medium chain acyl-CoA-dehydrogenase at the site of infection or in remote organs. Indeed, we observed similar changes in acylcarnitines and glycerophospholipids in liver and lung homogenates in models of pneumococcal disease [38]. These metabolite levels in plasma or MSCHAD or CROT enzyme concentrations in septic patients may be biomarkers of liver mitochondrial activity and hence show potential to contribute to the accuracy of risk assessment in septic patients.

Our study has limitations in terms of the number of patients enrolled, however the cost of the large number of biochemical and metabolomic tests performed on multiple samples per patient precluded enrolment of a much larger cohort. Hence, a certain care
is necessary when following up on our results, which should include confirmation in larger study cohorts. Machine learning can be used to derive biological phenotypes from routine data collected on septic patients. For example, Seymour et al. identified four clinical phenotypes that correlated with host-response patterns and clinical outcomes; subsequent simulations suggested these phenotypes could predict treatment effects [39]. Of note, and as reflective of routine clinical practice, metabolism barely featured in this analysis and was essentially limited to monitoring blood glucose, lactate, and blood urea nitrogen levels. However, a loss of metabolic homeostasis, most notably lipid and lipoprotein metabolism, is a commonplace event in critical illness [40]. Some overlap between these two distinct cohorts was however evident as the delta-phenotype described by Seymour et al [39], characterized by a greater degree of liver dysfunction and hyperlactatemia, and a poorer prognosis mirrors the conventional blood chemistry profile in our current study in those septic patients who ultimately died. As such, we extend this clinical delta-phenotype identifying metabolic derangements to the concept of metabolic ‘instability’ regarding key pathways, most notably mitochondrial and peroxisomal handling of medium and long-chain fatty acids. Fluctuations of these pathways outside the “corridor of safety” predict a poor outcome.

In conclusion, our study confirms and substantially extends the concept of a central role for (energy) metabolism to facilitate survival in sepsis (Fig. 4D). While this concept is increasingly accepted, several landmark studies targeting metabolism through enhancing oxygen availability [41,42] or nutritional support [43] have failed to yield clear benefit. Our study provides compelling evidence for a need to monitor these critical cellular functions beyond the currently available yet highly restricted portfolio of molecules, most notably glucose, urea and lactate. Furthermore, a loss of metabolic adaptation to sepsis appears to be reflected by an instability of cellular metabolism of fatty acids as characterized by falling outside a “corridor of safety” (Fig. 5).

4. Materials and methods

4.1. Patients

Patients enrolled participated in the STudying Responses of the Stress System in critical illness (STRESS) study. The study was approved by the NRES Committee East of England – Norfolk, REC reference 11/EE/0180. Written consent was given by the patient, if mentally competent, or by their next-of-kin with retrospective consent gained from surviving patients after they regained mental capacity. All patients admitted to the intensive care unit (ICU) were screened on a daily basis to assess those meeting entry and exclusion criteria.

Inclusion criteria

- Multi-organ failure (at least 2 organ systems involved)
- Initial SOFA score >3
- Predicted length of ICU stay >3 days

Exclusion criteria

- >24 h hospital admission prior to ICU admission
- Paediatric patients (age <18 years)
- Pregnant patients
- Severe psychiatric illness (patients at risk of suicide, those with schizophrenia, or those prescribed >1 anti-depressant medication)
- Patients who have used cortisol altering drugs within the preceding 6 weeks prior to admission (e.g. corticosteroids)

Fig. 5. The metabolic safety corridor concept. Metabolite concentrations falling outside a corridor of safety are associated with an increased risk of mortality.

- Cirrhosis (Child Pugh B or C classification)
- Severe brain injury (e.g. trauma, stroke, prolonged cardiac arrest)

Following ICU admission and enrolment into the study, clinical management was at the discretion of the treating clinicians. No treatment interventions were undertaken, and patients therefore received ‘usual’ ICU care. The patient sample size cohort characteristics can be found in Table 1.

4.2. Patients – blood sampling protocol

Blood samples were withdrawn from pre-inserted arterial lines within 6 h of ICU admission (day 0), and then repeated on days 1, 2, 3, 5 and 7 and weekly thereafter until day 28. A blood sample was also collected on the day of ICU discharge. Other than admission blood samples, all remaining samples were collected between 08:00 and 09:00 h each morning. In patients who did not have a patent arterial line, blood was instead aspirated from a central venous catheter (if present), or by venepuncture. Each blood sample consisted of 20 ml whole blood collected into previously sterilized collection vials and commercially available blood collection tubes (BCT). These consisted of one 5 ml BCT containing clot activator and gel for serum separation (BD Vacutainer Gold, BD Diagnostics, Franklin Lakes, New Jersey, USA) and one 4 ml BCT containing 4.2 mg spray-dried K2EDTA vial (BD Vacutainer Lavender). Additional 2.2 ml blood samples were collected into four sterile Eppendorf tubes; two plain tubes were used for serum samples (and allowed to clot for 30 min) and two tubes containing 2.2 mg EDTA di-potassium salt (Sigma-Aldrich, St Louis, MO, USA) for EDTA-plasma samples. An additional 1 ml blood sample was drawn into a chilled sterile Eppendorf tube containing 500 KIU/ml aprotinin (Trasylol, Bayer, Newbury, Berks, UK) and 1 mg EDTA to measure vasopressin. An additional 1 ml blood sample was drawn into a sterile Eppendorf tube containing 1 ml of the serine protease inhibitor AEBSF (Sigma-Aldrich) for measurement of unstable hormones. Hydrochloric acid (Sigma-Aldrich) was added to the AEBSF sample to a final concentration of 0.05 M post-centrifugation.

All samples except that for vasopressin were stored on ice immediately after collection and subsequently centrifuged at 6500 g for 10 min. The plasma or serum supernatants were then decanted into 200 µl aliquots, snap- frozen in liquid nitrogen and stored at −80 °C.
4.3. Patients – biochemical measurements and assays

For the measurement of biochemical parameters a range of instruments and techniques was employed. Urea, creatinine, ALT, AST, ALP, albumin, total cholesterol, HDL, LDL, triglycerides, TSH, free T₃ and T₄ were analyzed in clinical chemistry system (AU5800 analyzer, Beckman Coulter, Brea, California, USA). BNP, ACTH, gluconad, adrenaline and noradrenaline levels were measured by competitive ELISA (EELH0598, EELH0137, EELH2237, EELH0045 and EELH0047 respectively, Elabscience), as well as aldosterone (ADI-900-173, Enzo Life Sciences), TNT by electro-chemiluminescence immunoassay (Roche Diagnostics, Basel, Switzerland), Prolactin, growth hormone, IL6, IL10 and Leptin by sandwich ELISA (EELH0141, EELR0029, Elabscience, OptEIA Sets IL-6 & IL-10, BD Biosciences Pharmingen, San Diego, CA, USA, and KH2281, Invitrogen, respectively).

For vasopressin measurements samples were centrifuged at 1600g for 15 min at 4 °C and then frozen at –80 °C. After thawing twice the volume of ice-cold acetone was added to the sample, mixed, and then centrifuged at 12,000g for 20 min. The supernatant was transferred to a new tube. 5x the total volume of ice-cold petroleum ether was added and the solution then centrifuged at 10,000g for a further 10 min. The top layer of ether was discarded. The remaining aqueous layer was transferred to a glass tube and dried down with gaseous nitrogen. The samples were then reconstituted with assay buffer (Tris-buffered saline, TBS) and analyzed with competitive ELISA (ADI-900-017A, Enzo Life Sciences, Exeter, Devon, UK).

For testosterone measurements frozen serum samples were thawed. 1 ml of diethyl ether (Sigma-Aldrich) was added to 1 ml of serum sample. The tube was left in a fume hood and layers were allowed to separate, following which the top organic layered was siphoned off into a clean tube. This procedure was repeated three times. The diethyl ether was then evaporated under a stream of gaseous nitrogen. The extracted testosterone was dissolved in 250 µl of TBS. The reconstituted samples were analyzed with competitive ELISA (ab108666, Abcam). The same method was applied for estradiol. DHEA and cortisol were extracted using the same method and quantified using competitive ELISA (ADI-900-093, Enzo Life Sciences, and ab108665, Abcam, Cambridge, UK, respectively).

4.4. Rat sepsis model

Animal experiments were conducted using a long-term fluid-resuscitated rat fecal peritonitis model of sepsis. The study was undertaken following local ethics committee approval and a project licence granted by the UK Home Office (PPL70/7029: Organ dysfunction in critical illness states). Male Wistar rats (RGD Cat#13508588, RRID:RGD_13508588) (Charles River, Margate, Kent, UK) weighing between 325 and 375 g were housed in cages of four for a week prior to experimentation. Animals were sacrificed at either 6, 24 or 72 h with blood, liver and heart tissue sampled. These timepoints correspond to infection, established sepsis and recovery phases, respectively in this model; mortality generally occurs between 18 and 40 h with surviving animals showing clinical and biochemical signs of recovery at the study endpoint (72 h) [23–25].

All rats were assessed regularly using a validated clinical severity scoring system. A score ≥4 on two consecutive readings was deemed to be an indicator of excessive animal discomfort; due to welfare reasons such animals were sacrificed.

4.5. Rat model – Blood sampling protocol

Rats underwent instrumentation and echocardiography under brief general anaesthesia using isoflurane (Baxter Healthcare, Thetford, Norfolk, UK). An anaesthetic vapouriser (Vet-Tech Solutions, Congleton, Cheshire, UK) and air pump (TetraTec APS400, Tetra GmbH, Melle, Germany) were used to administer the anaesthetic. Rats were placed in a plastic induction chamber and anaesthesia induced using 5% isoflurane. Maintenance anaesthesia was achieved using 2% isoflurane with animals spontaneously breathing through a nose cone. Rats were then positioned supine on a heated mat with continuous monitoring of core temperature via a rectal thermometer (TES 1319, TES Electrical Electronic Corp, Taipei, Taiwan). Body temperature was maintained between 36.0 and 37.5 °C while under anaesthesia.

A chemical depilatory cream was used to remove hair from the neck and chest (Nair, Church and Dwight, Folkestone, Kent, UK). Preoperative skin preparation was completed using a commercially available mix of 2% chlorhexidine gluconate and 70% isopropyl alcohol (ChloraPrep, CareFusion, San Diego, CA, USA). A sterile skin drape was used and all surgical procedures performed with strict aseptic technique. A 2 cm vertical incision in the centre of the neck was used to obtain access to the right internal jugular vein and the left common carotid artery. Both vessels were cannulated with 0.96 mm outer diameter PVC tubing (Biocorp Ltd, Hunt- ingdale, NSW, Australia) and secured in place with two 3–0 silk sutures. This allowed continuous blood pressure monitoring and blood sampling through the arterial line, and fluid resuscitation through the venous line. Both lines were tunnelled subcutaneously to the nape of the neck and attached to a dual channel swivel and button tether system (InsTech Solomon, Plymouth Meeting, PA, USA) which was secured to the skin using four 2–0 silk sutures. The skin incision site was sutured using 3–0 silk sutures. To provide analgesia rats were given a subcutaneous injection of 0.05 mg/kg buprenorphine (Vetgesic, Reckitt Benckiser, York, UK) prior to recovery.

Following recovery from anaesthesia, animals were individually housed in metabolic cages with the swivel-tether system attached to a balancing arm. This allowed the rats unfettered movement in their cages with access to food and water ad libitum. Room temperature was kept at 21.1 ± 1.1 °C, humidity between 40 and 70%, and a 12-hour light–dark cycle was maintained.

Both venous and arterial lines were flushed continuously to maintain patency with 0.1 ml/h of 0.9% saline (Baxter Healthcare, Thetford, Norfolk, UK). The arterial line was connected to a pressure transducer (SensoNor SP844, Memscap, Skoppum, Norway) and blood pressure recorded continuously onto a Powerlab system (AD Instruments, Chalgrove, Oxon, UK).

4.6. Fecal peritonitis

Stool samples were obtained from six healthy non-vegetarian human volunteers and pooled together. Samples were collected in styrofoam containers, weighed and stored on ice. Collected fecal material was continuously fumigated with nitrogen in order to maintain an anaerobic environment. The collected material was diluted 1:1 with a suspension of thioglycolate (14.5 g/500 ml distilled water) and catalase (0.19 mg/100 ml) to optimize bacterial growth and inactivate reactive oxygen species. For cryoconservation 10% glycerine was added and the suspension homogenized under anaerobic conditions. The resulting material was divided into 0.5 ml aliquots and frozen at –80 °C. Prior to use each aliquot was thawed and diluted 1:7 with 0.9% saline to form faecal slurry. Sepsis was induced in the rats by intraperitonital (i.p.) injection of faecal slurry using a 19-gauge needle injected in the right lower quadrant of the abdomen. This was performed prior to recovery from anaesthesia, but after instrumentation. Sham operated controls received no i.p. placebo injection to avoid inadvertent bowel perforation. An initial pilot study ascertained the dose of faecal slurry producing a 24 h mortality rate of approximately 40%. This
mortality rate was selected as it reflects the mortality rate of human fecal peritonitis. It would also allow sufficient group sizes for comparisons between survivors and non-survivors for at least 24 h.

4.7. Fluid regimen

Fluid resuscitation (10 ml/kg/h) was initiated at two hours post-injection of faecal slurry. A 50:50 mix of Hartmann’s solution (a crystalloid solution closely isotonic to blood, containing sodium, chloride, potassium and calcium ions, and lactate) and 5% glucose were infused via the indwelling venous catheter. This fluid infusion rate was reduced to 5 ml/kg/h at 48 h. An identical fluid regimen was used for control animals. Glucose was added to avoid hypoglycemia.

4.8. Echocardiography

All rats underwent baseline transthoracic echocardiography (TTE) prior to insertion of vascular catheters. TTE was also performed at 6 h after induction of sepsis and a final examination at the end-point of the experiment. TTE was performed using a Vivid 7 Dimension device (GE Healthcare, Bedfont, Beds, UK) and a 10 MHz sector transducer (Vivid 10S, GE Healthcare). All variables were recorded under a brief period of 1.2% isoflurane anaesthesia. Stroke Volume and Cardiac Output used for prediction of Sepsis outcome was calculated as described elsewhere [24].

4.9. Rat model – biochemical measurements and assays

For arterial blood gas measurements we collected a 0.2 ml baseline blood sample from the arterial line into a heparinized capillary tube. Subsequent samples were collected at 6, 24 and 72 h. A 0.4 ml fluid bolus of 50:50 Hartmann’s and 5% glucose was administered to the animal after each sampling. The arterial blood was used to measure pH, PaO2, PaCO2, bicarbonate, base excess, total haemoglobin, sodium, potassium, ionized calcium, chloride and lactate (ABL-700, Radiometer, Copenhagen, Denmark). Rat troponin levels were measured by sandwich ELISA (EELR0151, Elabscience Biotechnology Co, Beijing, China). BNP levels were measured by competitive ELISA in rat samples (RAB0386, Sigma-Aldrich). Measurement of cystatin C was performed using a sandwich ELISA technique (EELR0304, Elabscience).

Markers of liver dysfunction were measured in rat samples by the biochemistry laboratory in the Royal Free Hospital, as mentioned earlier for patient samples. These markers included measurement of liver transaminases, alkaline phosphatase, bilirubin and albumin. To assess the anterior pituitary hormone, ACTH, measurement in serum samples was undertaken using a competitive ELISA technique (EELR0048, Elabscience). TSH was measured in rat samples using a sandwich ELISA (EELR0976, Elabscience). Rat growth hormone was analysed using a solid phase sandwich ELISA (Rat GH EIA Kit, Invitrogen Corporation, Camarillo, California, USA). Prolactin measurement was also performed using a sandwich ELISA method (EELR052, Elabscience). Vasopressin and oxytocin were extracted and is in patient samples. For determination of rat oxytocin levels, a competitive ELISA kit was used (CSB-E14197R, Cusabio Biotech, Maryland, USA). Levels of free T3 and T4 in rat samples were measured using competitive ELISA kits (EELR097 and EELR0390, Elabscience). Aldosterone levels were measured in EDTA plasma samples using competitive ELISA kits (ADI-900-173, Enzo Life Sciences). For measurement of rat levels of corticosterone (or cortisol) we followed the same procedure as for patient samples. Rat corticosterone levels were measured using a competitive ELISA kit (ADI-900-097, Enzo Life Sciences). Progesterone levels were determined using a competitive ELISA technique (CSB-E07282r, Cusabio). The procedure for testosterone measurement is the same as in patients. Rat testosterone levels were measured using a competitive ELISA kit (ADI-900-065, Enzo Life Sciences), 17b-estradiol measurements also involved an extraction procedure - identical to that described for testosterone. Measurement in rat samples was undertaken using a competitive ELISA method (ADI-900-008, Enzo Life Sciences). Similarly, DHEA also required hormone extraction from blood samples (again using the same technique). DHEA levels were measured using competitive ELISA kits (ADI-900-093, Enzo Life Sciences). For ghrelin measurements blood samples were drawn into pre-chilled tubes containing AEBSF to a final concentration of 1 mg/mL. These samples were centrifuged at 3000 g for 15 min at 4 °C. Serum was then transferred to separate tubes and acidified with HCl (Sigma-Aldrich) to a final concentration of 0.05 M. Samples were then snap frozen in liquid nitrogen and stored at −80 °C for later analysis by ELISA. Ghrelin was measured in rat samples using commercially available sandwich ELISA kits (EMD Millipore). Leptin was measured in rat and human samples using a sandwich ELISA method (KRC2281 and KHC2281, Invitrogen). Epinephrine measurement in EDTA plasma samples was performed using competitive ELISA kits (EELR0045, Elabscience). For determining levels of norepinephrine, a similar kit was used (EELR0047, Elabscience) Measurement of the cytokines IL-6 and IL-10 was undertaken using sandwich ELISA kits (OptEIA Sets IL-6 & IL-10, BD Biosciences Pharmingen, San Diego, CA, USA). Measurement of both complement C5a and C5a in rat samples was performed using sandwich ELISA (EELR0255 and EELR0257, Elabscience). Glucose and lactate measurements were performed using arterial blood samples that were analysed in a commercially available blood gas machine (ABL-700, Radiometer, Copenhagen, Denmark). Insulin levels were measured in EDTA plasma samples using sandwich ELISA methods (EZRMI-13K and EZHI-14K, EMD Millipore). For measurement of glucagon competitive ELISA methods were used for both rat and patient studies (EELR0425, Elabscience).

Measurement of ketone bodies (total, 3-hydroxybutyrate and acetoacetone) was performed using a cyclic enzymatic method (Wako Chemicals GmbH, Neuss, Germany). Samples were measured on a 96-well microtitre plate in triplicate. To each sample, a buffer mixture was added containing phosphate buffer pH7.0 and acetoacetate decarboxylase, resulting in acetoacetone breakdown to acetone. Subsequent addition of thionicotinamide adenine dinucleotide (Thio-NAD) and the enzyme 3-hydroxybutyrate dehydrogenase (3-HBDH) resulted in oxidation of 3-HB. Since the original acetoacetone in the sample had been removed, only 3-HB was assayed by measuring the rate of Thio-NADH production spectrophotometrically.

For measuring glycerol and free fatty acids coupled enzymatic reactions were used in commercially available kits (Cayman Chemical Company, Michigan, USA). The glycerol assay involved a series of enzymatic chemical reactions that resulted in glycerol phosphorylation, and subsequent oxidation, ultimately producing hydrogen peroxide. The hydrogen peroxide then reacted with 4-aminoantipyrine (4-AAP) and N-ethyl-N-(3-sulfopropyl)-m-anisidine (ESPA) resulting in production of a brilliant purple product, which could be measured in the wells of a microtitre plate using a plate reader set at 540 nm. A standard curve using glycerol reference standards was used to calculate sample glycerol concentrations.

Free fatty acids (FFA) were measured in a fluorometric assay that involved a series of coupled enzymatic reactions (Cayman Chemical Company, Michigan, USA). Acyl CoA synthetase first catalysed FFA acylation of coenzyme A. The acyl CoA produced was oxidised by acyl CoA oxidase and generated hydrogen peroxide. Hydrogen peroxide reacted with horseradish peroxidase to generate the highly fluorescent product resorufin. Resorufin fluo-
resonace was measured using a fluorometric plate reader, with an
excitation wavelength of 530–540 nm and an emission wavelength
of 585–595 nm. A standard curve using FFA reference standards
was used to calculate sample FFA concentrations.

HDL cholesterol, LDL cholesterol and triglycerides were mea-
sured on an industrial clinical chemistry system (AU5800 analyzer,
Beckman Coulter, Brea, California, USA).

4.10. Metabolomic measurements

For targeted metabolomics of patient and rat samples, in brief, 188
metabolites (acylcarnitines, amino acids, biogenic amines,
glycerophospholipids, sphingolipids, and sugars) were quantified
in plasma using the AbsoluteDQ® kit p180 (Biocrates Life Science
AG, Innsbruck, Austria) according to the manufacturer’s protocol
on an AP4000 liquid chromatography tandem mass spectrometry
(LC-MS/MS) system (AB Sciex, Framingham, MA) equipped with an
electrospray ionization source, a CTC PAL autosampler (CTC Ana-
lytics AG, Switzerland), and the Analyst 1.6.2 software (AB Sciex).
Further treatment details are described elsewhere [44]. The MetIQ
software package, which is an integral part of the AbsoluteDQ® kit
(Biocrates Life Science AG, Innsbruck, Austria), was used for eval-
uation of calibration curves, quality controls and samples. For statis-
tical analysis concentrations were exported. Using nonphysiological or similar standards some of the metabolites,
especially glycerophospholipids, were determined only semiquantitatively.

4.11. Quantification and statistical analysis

Dimensionality reduction was done with PCA based on the sam-
ple distance matrix. We chose the Canberra distance as the dis-
tance metric to deal with the skewness common within metabolomics data [45]. The significance of group differences in the
resulting PCA biplots and patient centroids was calculated
using PERMANOVA with the vegan package with euclidean dis-
tance on the reduced data points. The bias from group imbalance
was circumvented by averaging p-values over at least 1000 repeats
of random sampling with equal proportions.

For patients, statistical analysis of biochemical parameter
and metabolite time courses at days 0–3 was performed using repeated
measures two-way mixed effects type-III ANOVA [46] with the
categorical effects day, survival and their interaction. We controlled
for multiple hypotheses testing using FDR correction for each
metabolite. We reported metabolites and biochemical parameters
when the q value for the survival effect or its interaction with
day was < 0.05. To further find those days at which significant dif-
ferences occurred we used Tukey HSD from the multcomp package
[47]. For rat samples, statistical analysis of biochemical parameter
and metabolite time courses at times 6 h and 24 h was done using repeated
two-way mixed effects type-III ANOVA [46] with the cat-
egorical effects timepoint, survival and their interaction. We con-
trolled for multiple hypotheses testing using FDR correction for
each metabolite. We report metabolites and biochemical param-
eters when the q value for the survival effect or its interaction with
timepoint was below 0.05. To further find the time points at which
significant differences occur we used Tukey HSD from the multi-
comp package [47].

Survival prediction was done with Random Forests and linear
support vector machines (SVMs) from the ranger [28] and e1073
[48] packages, respectively. Tournament Leave Pair Out Cross Val-
idation (TLPO-CV) procedure [31] together with recursive feature
elimination in an inner TLPO-CV loop was used to most effectively
use given samples for feature selection and validation. Briefly, for
each single pair in the outer TLPO-CV loop, TLPO-CV was per-
formed on all sample pairs that do not use the samples from the
outer sample pair and the variable importance was averaged across
all inner sample pairs. The least important variables were removed
stepwise until two variables remained. The classification perfor-
ance obtained in the inner TLPO-CV loop was then validated in
the outer TLPO-CV loop on sample pairs not used in the inner
TLPO-CV loops.

Augmented KEGG pathway maps [49] were created with the
Pathview package [50].

Significance tests of the number of deviations from the corridor
of safety for patients and for metabolites were done by simulation
tests as follows. All measurement values were replaced by random
lognormal values from the same distribution and the number of
deviations counted. This was repeated 1000 times and the fraction
of occurrence of deviation counts calculated. P values were then
calculated as the sum of fractional occurrences for deviations
as extreme or more extreme and assigned to each metabolite accord-
ting to their true deviation count. Q values were calculated from the
p values of all metabolites as the FDR.

Kinetic metabolic modelling was done by combining COPASI
4.25 (COPASI, RRID:SCR_014260) [51] and the COPASI R Connector
version 0.5. The parameter fit was set up in COPASI with a five-fold
increase and decrease from the preset V max values [52] as upper
and lower bounds for V max parameters, and a two-fold increase
and decrease as upper and lower bounds for the initial concentra-
tions to support the physiological relevance of the model. For each
data we fitted the ratio of Septic-S concentration to total concentra-
tions of Septic-S and Septic-NS on the actual day and the next day.
Every consecutive day reused the fitting outcome of the previous
day. The fitting itself was done by first applying an evolutionary
strategy and, secondly, the Hooke-Jeeves algorithm. To deduce
enzyme concentrations from model simulations we allowed the
model to fit maximum velocity parameters (V max) which are a pro-
duct of total enzyme concentration and the fixed velocity constant
of a single enzyme molecule. Hence, higher fitted V max values indi-
cate increased enzyme concentrations as enzymatic maximum
turnover rates are limited. We deduced reaction fluxes and concen-
trations from steady state analysis. To ensure robustness we
repeated the parameter fitting 100 times with random start values.

5. Data and code availability

The published article includes all datasets generated and anal-
yzed during this study. The complete code used to analyse the data
generated during this study is available at github (https://github.
com/SchSascha/KhaliqGrossmann2020_sepsis_metabolomics).

CRediT authorship contribution statement

Waqas Khaliq: Conceptualization, Data curation, Investigation,
Methodology, Project administration, Validation, Writing - review
& editing. Peter Großmann: Formal analysis, Methodology, Visual-
ization, Writing - original draft, Writing - review & editing. Sophie
Neugebauer: Data curation, Formal analysis, Investigation, Writing
- review & editing. Anna Kleyman: Investigation, Writing - review
& editing. Roberta Domizi: Data curation, Investigation, Writing
- review & editing. Sara Calculino: Data curation, Investigation,
Writing - review & editing. David Brealey: Data curation, Investi-
gation, Methodology, Project administration, Writing - review &
editing. Markus Gräler: Supervision, Writing - review & editing.
Michael Kiehntopf: Methodology, Supervision, Writing - review &
editing. Mervyn Singer: Conceptualization, Funding acquisition,
Methodology, Project administration, Resources, Supervision, Writing
- original draft, Writing - review & editing. Gianni Panagiotou: Project administration, Resources,
Supervision, Writing - original draft, Writing - review & editing. Michael Bauer: Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Writing - original draft, Writing - review & editing.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

GPA, MB and PG would like to thank Deutsche Forschungsgemeinschaft (DFG - www.dfg.de) CRC/Transregio 124 “Pathogenic fungi and their human host: Networks of interaction” (DFG project number 210879364), subproject INF and CS. GPA and MB would like to thank the Deutsche Forschungsgemeinschaft (DFG - www.dfg.de) cluster of excellence “Balance of the Microverse” DFG-EXC 2051. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.csbj.2020.11.009.

References

[1] Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016;315(8):801.
[2] Fleischmann C, Scherag A, Adhikari NKJ, Hartog CS, Tsagarakis K, Schuetz P, et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med 2016;193(3):259–72.
[3] Prescott HC, Angus DC. Enhancing recovery from sepsis: a review. JAMA 2018;319(1):62–73.
[4] Martin GS, Mannino DM, Moss M. The effect of age on the development and outcome of adult sepsis. Crit Care Med 2006;34(1):15–20.
[5] Marriot I, Huet-Hudson YM. Sexual dimorphism in innate immune responses to infectious organisms. Immunol Rev 2006;204(1):177–92.
[6] Sinapidis D, Kosmas V, Vittoros V, Koutelidakis IM, Pantazi A, Stafos A, et al. Progression into sepsis: an individualized process varying by the interaction of comorbidities with the underlying infection. BMC Infect Dis 2018;18(1):242.
[7] Kautanen A, Mills TC, Gordon AC, Hutton P, Steffens M, Numan R, et al. Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study. Lancet Resp Med 2015;3(1):53–60.
[8] Schrag SJ, Farley MM, Pettit S, Reingold A, Weston EJ, Pondo T, et al. Epidemiology of invasive early-onset neonatal sepsis, 2005 to 2014. Pediatrics. 2016;138(6):e20162034.
[9] Ang D, van der Poll T. Severe sepsis and septic shock. N Engl J Med 2013;368(9):840–51.
[10] Antti H, Fahlgren A, Näsström E, Kouremenos K, Sundén-Cullberg J, Guo Y, et al. Fungus and their human host: Networks of interaction” (DFG project number 210879364), subproject INF and CS. GPA and MB would like to thank the Deutsche Forschungsgemeinschaft (DFG - www.dfg.de) cluster of excellence “Balance of the Microverse” DFG-EXC 2051. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.csbj.2020.11.009.

References

[1] Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016;315(8):801.
[2] Fleischmann C, Scherag A, Adhikari NKJ, Hartog CS, Tsagarakis K, Schuetz P, et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med 2016;193(3):259–72.
[3] Prescott HC, Angus DC. Enhancing recovery from sepsis: a review. JAMA 2018;319(1):62–73.
[4] Martin GS, Mannino DM, Moss M. The effect of age on the development and outcome of adult sepsis. Crit Care Med 2006;34(1):15–20.
[5] Marriot I, Huet-Hudson YM. Sexual dimorphism in innate immune responses to infectious organisms. Immunol Rev 2006;204(1):177–92.
[6] Sinapidis D, Kosmas V, Vittoros V, Koutelidakis IM, Pantazi A, Stafos A, et al. Progression into sepsis: an individualized process varying by the interaction of comorbidities with the underlying infection. BMC Infect Dis 2018;18(1):242.
[7] Kautanen A, Mills TC, Gordon AC, Hutton P, Steffens M, Numan R, et al. Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study. Lancet Resp Med 2015;3(1):53–60.
[8] Schrag SJ, Farley MM, Pettit S, Reingold A, Weston EJ, Pondo T, et al. Epidemiology of invasive early-onset neonatal sepsis, 2005 to 2014. Pediatrics. 2016;138(6):e20162034.
[9] Ang D, van der Poll T. Severe sepsis and septic shock. N Engl J Med 2013;368(9):840–51.
[10] Antti H, Fahlgren A, Näsström E, Kouremenos K, Sundén-Cullberg J, Guo Y, et al. Fungus and their human host: Networks of interaction” (DFG project number 210879364), subproject INF and CS. GPA and MB would like to thank the Deutsche Forschungsgemeinschaft (DFG - www.dfg.de) cluster of excellence “Balance of the Microverse” DFG-EXC 2051. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.csbj.2020.11.009.

References

[1] Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016;315(8):801.
[2] Fleischmann C, Scherag A, Adhikari NKJ, Hartog CS, Tsagarakis K, Schuetz P, et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med 2016;193(3):259–72.
[3] Prescott HC, Angus DC. Enhancing recovery from sepsis: a review. JAMA 2018;319(1):62–73.
[4] Martin GS, Mannino DM, Moss M. The effect of age on the development and outcome of adult sepsis. Crit Care Med 2006;34(1):15–20.
[5] Marriot I, Huet-Hudson YM. Sexual dimorphism in innate immune responses to infectious organisms. Immunol Rev 2006;204(1):177–92.
[6] Sinapidis D, Kosmas V, Vittoros V, Koutelidakis IM, Pantazi A, Stafos A, et al. Progression into sepsis: an individualized process varying by the interaction of comorbidities with the underlying infection. BMC Infect Dis 2018;18(1):242.
[7] Kautanen A, Mills TC, Gordon AC, Hutton P, Steffens M, Numan R, et al. Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study. Lancet Resp Med 2015;3(1):53–60.
[8] Schrag SJ, Farley MM, Pettit S, Reingold A, Weston EJ, Pondo T, et al. Epidemiology of invasive early-onset neonatal sepsis, 2005 to 2014. Pediatrics. 2016;138(6):e20162034.
[9] Ang D, van der Poll T. Severe sepsis and septic shock. N Engl J Med 2013;368(9):840–51.
[10] Antti H, Fahlgren A, Näsström E, Kouremenos K, Sundén-Cullberg J, Guo Y, et al. Fungus and their human host: Networks of interaction” (DFG project number 210879364), subproject INF and CS. GPA and MB would like to thank the Deutsche Forschungsgemeinschaft (DFG - www.dfg.de) cluster of excellence “Balance of the Microverse” DFG-EXC 2051. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.csbj.2020.11.009.
